Work

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Year: 2020

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-20-1408

Authors: Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George, Michael B. Atkins

Institutions: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Vanderbilt University Medical Center, Moffitt Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Pfizer (United States), Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W3052860595

FWCI: 2.336

Cites: 41

Cited by: 27

Related to: 10